Oxidative stress parameters in patients with ascending aortic dilatation
Ascending aortic dilatation
ferroxidase
oxidative stress
thiols
ischemia modified albumin
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
26 08 2020
26 08 2020
Historique:
received:
28
09
2019
accepted:
16
05
2020
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
13
7
2021
Statut:
epublish
Résumé
This study aimed to determine plasma thiol, disulphide, and serum ischemia-modified albumin (IMA) levels and ferroxidase activity in patients with ascending aorta dilatation (AAD) in comparison to those without AAD and to evaluate the predictive value of these oxidative stress parameters for AAD. This study was designed as a cross-sectional study of 184 patients who applied to our cardiology clinic. Our study population consisted of patients with AAD (n = 85) and without AAD (n = 99). A spectrophotometric method was used to determine plasma thiol, disulphide, and serum IMA levels and ferroxidase activity. The native thiol and the total thiol levels were significantly higher in the control group than the AAD group (P < 0.001), whereas the disulphide and IMA levels and the ferroxidase activity were similar between the groups. The native thiol and the total thiol levels were inversely and significantly correlated with ascending aortic diameter (r = –0.38, P < 0.001; r = –0.39, P < 0.001; respectively). The left ventricle mass and the total thiol levels were independent predictors of ascending aortic diameter (β= 0.223, P = 0.02; β= –0.340, P < 0.001; respectively). Among oxidative stress parameters including thiols, disulphide, IMA, and ferroxidase activity, only the lower total thiol levels appear to confer a high risk for AAD development. Along with the proven diagnostic imaging methods, thiol levels may be helpful to diagnose and stratify patients with AAD.
Sections du résumé
Background/aim
This study aimed to determine plasma thiol, disulphide, and serum ischemia-modified albumin (IMA) levels and ferroxidase activity in patients with ascending aorta dilatation (AAD) in comparison to those without AAD and to evaluate the predictive value of these oxidative stress parameters for AAD.
Materials and methods
This study was designed as a cross-sectional study of 184 patients who applied to our cardiology clinic. Our study population consisted of patients with AAD (n = 85) and without AAD (n = 99). A spectrophotometric method was used to determine plasma thiol, disulphide, and serum IMA levels and ferroxidase activity.
Results
The native thiol and the total thiol levels were significantly higher in the control group than the AAD group (P < 0.001), whereas the disulphide and IMA levels and the ferroxidase activity were similar between the groups. The native thiol and the total thiol levels were inversely and significantly correlated with ascending aortic diameter (r = –0.38, P < 0.001; r = –0.39, P < 0.001; respectively). The left ventricle mass and the total thiol levels were independent predictors of ascending aortic diameter (β= 0.223, P = 0.02; β= –0.340, P < 0.001; respectively).
Conclusion
Among oxidative stress parameters including thiols, disulphide, IMA, and ferroxidase activity, only the lower total thiol levels appear to confer a high risk for AAD development. Along with the proven diagnostic imaging methods, thiol levels may be helpful to diagnose and stratify patients with AAD.
Identifiants
pubmed: 32421280
doi: 10.3906/sag-1909-183
pmc: PMC7491292
doi:
Substances chimiques
Biomarkers
0
Disulfides
0
Sulfhydryl Compounds
0
ischemia-modified albumin
0
Ceruloplasmin
EC 1.16.3.1
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1323-1329Informations de copyright
This work is licensed under a Creative Commons Attribution 4.0 International License.
Déclaration de conflit d'intérêts
All the authors declare no conflict of interest.
Références
In Vivo. 2014 Nov-Dec;28(6):1197-200
pubmed: 25398823
J Am Coll Cardiol. 2006 Mar 7;47(5):1005-11
pubmed: 16516085
Heart Vessels. 2012 Jul;27(4):391-7
pubmed: 21698349
Cancer Res. 2014 Feb 1;74(3):787-96
pubmed: 24351290
Eur J Echocardiogr. 2006 Mar;7(2):79-108
pubmed: 16458610
Clin Chem. 1998 Nov;44(11):2313-9
pubmed: 9799759
Clin Biochem. 2014 Dec;47(18):326-32
pubmed: 25304913
Eur J Echocardiogr. 2010 Sep;11(8):645-58
pubmed: 20823280
Anadolu Kardiyol Derg. 2014 Mar;14(2):106-14
pubmed: 24449621
J Emerg Med. 2000 Nov;19(4):311-5
pubmed: 11074321
Eurasian J Med. 2014 Jun;46(2):89-95
pubmed: 25610305
Am J Hypertens. 2006 Apr;19(4):361-5
pubmed: 16580570
Br J Nutr. 1999 Feb;81(2):139-44
pubmed: 10450332
Circulation. 1997 Oct 7;96(7):2115-7
pubmed: 9337176
Arterioscler Thromb. 1991 Nov-Dec;11(6):1667-77
pubmed: 1931869
Scand Cardiovasc J. 2015 Apr;49(2):95-100
pubmed: 25658436
Turk J Med Sci. 2014;44(1):62-7
pubmed: 25558560
J Clin Invest. 1990 May;85(5):1343-52
pubmed: 2185272
Exp Mol Pathol. 2017 Feb;102(1):32-40
pubmed: 27955986
Molecules. 2010 Dec 06;15(12):8890-903
pubmed: 21135801
Circulation. 1997 Jan 7;95(1):205-12
pubmed: 8994438
Interact Cardiovasc Thorac Surg. 2012 Nov;15(5):871-7
pubmed: 22843654
J Clin Lab Anal. 2010;24(6):399-402
pubmed: 21089170
Blood Press Monit. 2016 Aug;21(4):238-43
pubmed: 27003944
Clin Chem Lab Med. 2011 Feb;49(2):177-84
pubmed: 21083441
Kardiol Pol. 2017;75(10):1020-1026
pubmed: 28715076
Am J Hypertens. 2011 Feb;24(2):149-54
pubmed: 20948528
Biomark Med. 2018 Apr;12(4):349-358
pubmed: 29436236